The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Collection
2.2. Determination of Serum Levels by ELISA
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Geneve, N.; Kairys, D.; Bean, B.; Provost, T.; Mathew, R.; Taheri, N. Colorectal cancer screening. Prim. Care 2019, 46, 135–148. [Google Scholar] [CrossRef] [PubMed]
- Aydin, I.; Sehitoglu, I.; Özer, E.; Yücel, A.; Pergel, A.; Bedir, R. The evaluation of patients operated due to colorectal cancer. Kocaeli Med. J. 2015, 16, 102–109. [Google Scholar]
- Roncucci, L.; Mariani, F. Prevention of colorectal cancer: How many tools do we have in our basket? Eur. J. Intern. Med. 2015, 26, 752–756. [Google Scholar] [CrossRef] [PubMed]
- Brenner, H.; Kloor, M.; Pox, C.P. Colorectal cancer. Lancet 2014, 383, 1490–1502. [Google Scholar] [CrossRef]
- Tse, J.C.; Kalluri, R. Mechanisms of metastasis: Epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell Biochem. 2007, 101, 816–829. [Google Scholar] [CrossRef] [PubMed]
- Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27, 5904–5912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392–401. [Google Scholar] [CrossRef] [PubMed]
- Scheller, J.; Engelowski, E.; Moll, J.M.; Floss, D.M. Immunoreceptor engineering and synthetic cytokine signaling for therapeutics. Trends Immunol. 2019, 40, 258–272. [Google Scholar] [CrossRef]
- Krzystek-Korpacka, M.; Zawadzki, M.; Kapturkiewicz, B.; Lewandowska, P.; Bednarz-Misa, I.; Gorska, S. Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine 2018, 110, 435–441. [Google Scholar] [CrossRef]
- Koi, M.; Carethers, J.M. The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncol. 2017, 13, 1633–1647. [Google Scholar] [CrossRef]
- Caglan, M.; Kansu, E. Chemokines, chemokine receptors and inflammation. ANKEM Derg. 2014, 18, 164–168. [Google Scholar]
- Marcuzzi, E.; Angioni, R.; Molon, B.; Calì, B. Chemokines and chemokine receptors: Orchestrating tumor metastasization. Int. J. Mol. Sci. 2018, 20. [Google Scholar] [CrossRef] [PubMed]
- Moran, C.J.; Arenberg, D.A.; Huang, C.C.; Giordano, T.J.; Thomas, D.G.; Misek, D.E.; Chen, G.; Iannettoni, M.D.; Orringer, M.B.; Hansah, S.; et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 2002, 8, 3803–3812. [Google Scholar] [PubMed]
- Aldinucci, D.; Colombatti, A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014, 292376. [Google Scholar] [CrossRef] [PubMed]
- Chang, L.Y.; Lin, Y.C.; Mahalingam, J.; Huang, C.T.; Chen, T.W.; Kang, C.W.; Chu, Y.Y.; Dutta, A.; Day, Y.J.; Chen, T.C.; et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012, 72, 1092–1102. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.; Liu, Q.; Tsang, L.L.; Ye, Q.; Chan, H.C.; Sun, Y. Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression via CCL5/β-catenin/Slug pathway. Cell Death Dis. 2017, 8, e2819. [Google Scholar] [CrossRef]
- Wang, J.; Li, G.; Ma, H.; Bao, Y.; Wang, X.; Zhou, H. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum. Pathol. 2007, 38, 1649–1656. [Google Scholar] [CrossRef]
- Wang, J.; Kataoka, H.; Suzuki, M.; Sato, N.; Nakamura, R.; Tao, H. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005, 24, 5637–5647. [Google Scholar] [CrossRef]
- Herath, N.I.; Spanevello, M.D.; Doecke, J.D.; Smith, F.M.; Pouponnot, C.; Boyd, A.W. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur. J. Cancer 2012, 48, 753–762. [Google Scholar] [CrossRef]
- Demoulin, J.B.; Essaghir, A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014, 25, 273–283. [Google Scholar] [CrossRef]
- Aydemir, B.; Karadag-Sari, E. The effects of platelet derived growth factor upon the structure, functions and growth. Atatürk Üniversitesi Vet Bil Derg. 2009, 4, 209–214. [Google Scholar]
- Farooqi, A.A.; Siddik, Z.H. Platelet-derived growth factor (PDGF) signalling in cancer: Rapidly emerging signalling landscape. Cell Biochem. Funct. 2015, 33, 257–265. [Google Scholar] [CrossRef] [PubMed]
- Manzat Saplacan, R.M.; Balacescu, L.; Gherman, C.; Chira, R.I.; Craiu, A.; Mircea, P.A. The role of PDGFs and PDGFRs in colorectal cancer. Mediators Inflamm. 2017. [Google Scholar] [CrossRef] [PubMed]
- Ye, X.; Liu, S.; Hu, M.; Song, Y.; Huang, H.; Zhong, Y. CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and β-arrestin2 expression. Scand. J. Gastroenterol. 2017, 52, 551–557. [Google Scholar] [CrossRef]
- Mencarelli, A.; Cipriani, S.; Francisci, D.; Santucci, L.; Baldelli, F.; Distrutti, E. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci. Rep. 2016, 6, 30802. [Google Scholar] [CrossRef] [PubMed]
- Velasco-Velázquez, M.; Xolalpa, W.; Pestell, R.G. The potential to target CCL5/CCR5 in breast cancer. Expert Opin. Ther. Targets 2014, 18, 1265–1275. [Google Scholar] [CrossRef] [PubMed]
- Sugasawa, H.; Ichikura, T.; Kinoshita, M.; Ono, S.; Majima, T.; Tsujimoto, H. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int. J. Cancer. 2008, 122, 2535–2541. [Google Scholar] [CrossRef]
- Tanabe, Y.; Sasaki, S.; Mukaida, N.; Baba, T. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation. Oncotarget 2016, 7, 48335–48345. [Google Scholar] [CrossRef] [PubMed]
- Cambien, B.; Richard-Fiardo, P.; Karimdjee, B.F.; Martini, V.; Ferrua, B.; Pitard, B. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS ONE 2011, 6, e28842. [Google Scholar] [CrossRef]
- Elenbaas, B.; Weinberg, R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 2001, 264, 169–184. [Google Scholar] [CrossRef] [PubMed]
- Sasaki, S.; Baba, T.; Shinagawa, K.; Matsushima, K.; Mukaida, N. Crucial involvement of the CCL3-CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. Int. J. Cancer 2014, 135, 1297–1306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tudoran, O.M.; Soritau, O.; Balacescu, L.; Pop, L.; Meurice, G.; Visan, S. PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. J. Cell Mol. Med. 2015, 19, 371–382. [Google Scholar] [CrossRef] [PubMed]
Assay | Patients (n = 70) | Controls (n = 40) | p | ||
---|---|---|---|---|---|
Mean | Range | Mean | Range | ||
PDGF (ng/L) | 375.9 | 9.6–4039.8 | 16.7 | 4.5–125.4 | <0.001 |
EphA7 (ng/mL) | 31.9 | 1.2–234.6 | 1.5 | 0.1–222.1 | <0.001 |
CCR5 (pg/mL) | 123.9 | 15.6–1891.5 | 24.2 | 0.4–560 | <0.001 |
CCL5 (ng/L) | 108.5 | 1.2–828.6 | 40 | 10.4–793 | <0.001 |
Univariate Model | Multivariate Reduced Model | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p | OR | 95% CI | p | |||||
PDGF-BB | 1.02 | 1.01 | - | 1.03 | 0.002 | 1.03 | 1.01 | - | 1.04 | 0.002 |
EphA7 | 1.03 | 1.01 | - | 1.05 | 0.003 | 1.02 | 1.01 | - | 1.04 | 0.005 |
CCR5 | 1.01 | 1.00 | - | 1.01 | 0.011 | |||||
CCL5 | 1.00 | 1.00 | - | 1.01 | 0.002 | 1.00 | 1.00 | - | 1.01 | 0.003 |
Age | 1.01 | 0.98 | - | 1.05 | 0.245 | |||||
Sex | 0.66 | 0.29 | - | 1.45 | 0.299 |
Test Variables | AUC | Asymptotic Sig.b | Asymptotic 95% Confidence Interval | |
---|---|---|---|---|
Lower Bound | Upper Bound | |||
PDGF-BB | 0.894 | 0.000 | 0.837 | 0.951 |
PDGF-EPhA7 | 0.938 | 0.000 | 0.896 | 0.979 |
PDGF-Epha-CCL5 | 0.958 | 0.000 | 0.926 | 0.990 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Üçüncü, M.; Serilmez, M.; Sarı, M.; Bademler, S.; Karabulut, S. The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer. Biomolecules 2019, 9, 464. https://doi.org/10.3390/biom9090464
Üçüncü M, Serilmez M, Sarı M, Bademler S, Karabulut S. The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer. Biomolecules. 2019; 9(9):464. https://doi.org/10.3390/biom9090464
Chicago/Turabian StyleÜçüncü, Muhammed, Murat Serilmez, Murat Sarı, Süleyman Bademler, and Senem Karabulut. 2019. "The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer" Biomolecules 9, no. 9: 464. https://doi.org/10.3390/biom9090464